This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 25, 2013 /PRNewswire/ -- NeuroSigma, Inc., a
California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive
Monarch™ eTNS™ System for the adjunctive treatment of epilepsy and depression, at the 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures to be held in
Salzburg, Austria from
April 4-6, 2013.
NeuroSigma's exhibit will feature the
Monarch neuromodulation system. Conference attendees will be able to learn about the device and its safety and efficacy for patients whose epilepsy remains poorly controlled with drug therapy. NeuroSigma will be represented at the conference by Leon Ekchian, Ph.D., President and CEO,
Christopher DeGiorgio, M.D., Vice President of Neurology at NeuroSigma and Professor of Neurology at the
University of California Los Angeles (
Colin Kealey, M.D., Manager of Business Development.
Case Study of the Use of eTNS for Status Epilepticus in the ICU
Status epilepticus is a life-threatening neurological emergency characterized by multiple or continuous seizures lasting longer than 5-10 minutes. Approximately 30-40% of patients with status epilepticus may develop refractory status epilepticus, where seizures continue longer than 1-hour after failing to respond to two or more antiepileptic drugs. Refractory status epilepticus is very lethal, with a mortality of 30-40%, and serious risk of neurological impairment. In
the United States approximately 152,000 cases of status epilepticus occur annually, resulting in about 42,000 deaths and an inpatient cost of
$3.8 to $7 billion per year.
Brian Moseley, M.D., a Fellow in the UCLA Department of Neurology, will present a case study in which external Trigeminal Nerve Stimulation (eTNS) was used successfully at
UCLA as an adjunctive treatment of refractory status epilepticus on a patient who had failed multiple drug therapies prior to eTNS and was in a medication-induced coma. Subsequent to treatment with eTNS, the patient regained consciousness and was eventually discharged. This will be the first report of the potential clinical utility of eTNS as adjunctive treatment in refractory status epilepticus.
Given the portability of the
Monarch eTNSSystem and its non-invasive nature, the case study suggests applicability of the Monarch as adjunctive treatment of refractory status epilepticus in an Intensive Care Unit (ICU) or emergency setting.
eTNS in the European Union
NeuroSigma's first TNS product, the
Monarch™ eTNS™ System, is currently being marketed to patients in the European Union (EU), with a physician's prescription. In
September 2012, NeuroSigma received
CE Mark approval for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older in the EU. The
Monarch was recently unveiled in
the 10th European Congress on Epileptology. The
Monarch™ eTNS™ System consists of a small stimulator that can be placed in a pocket or worn at the waist, and an electric patch that is placed on the forehead. The patch stimulates the trigeminal nerve through the surface of the skin, and is used primarily while the patient is asleep.
Background - TNS
The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain. The trigeminal nerve projects to specific areas of the brain, such as the locus coeruleus, nucleus tractus solitarius, thalamus and the cerebral cortex, which are involved in epilepsy, depression, PTSD, ADHD and other disorders. Trigeminal Nerve Stimulation (TNS) is the electrical stimulation of branches of the trigeminal nerve, which are located very close to the surface of the skin in the forehead. The low-energy stimulus is confined to the soft tissues of the forehead without direct penetration into the brain. PET imaging studies in humans confirm that eTNS activates or inhibits key regions implicated in these disorders and the changes were observed within minutes of therapy.